Polyethylene glycol compared to lactulose for constipation in pregnancy: A randomized controlled trial
International Journal of Gynecology & Obstetrics · 2024-08 · 166 (2) · 828-836
DOI: 10.1002/ijgo.15431 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Gynecology & Obstetrics, online erschienen am 23.02.2024. Verfasst von Victoria Ivy Raj und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Faculty of Medicine, University Malaya, Jalan Profesor Diraja Ungku Aziz, Kuala Lumpur, Malaysia. Hauptthemen laut MEDLINE: Constipation, Lactulose, Polyethylene Glycols, Pregnancy Complications. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Objective
To compare polyethylene glycol 4000 versus lactulose in chronic constipation during pregnancy.
Methods
Women at 28–32 weeks' gestation attending antenatal clinic for routine care were screened using the Rome IV chronic constipation criterion. Eligible women were approached and consented. Participants were randomized to oral polyethylene glycol (10 g/day) or lactulose (10 g/day) for 4 weeks. A bowel movement diary was kept and outcomes using the Patient Assessment of Constipation Symptoms questionnaire (PAC‐SYM), Patient Assessment of Constipation Quality of Life questionnaire (PAC‐QoL) and Bristol Stool Form Scale (BSFS), which were evaluated at the start and end of the four‐week period. Relative risks (RR) were determined for the coprimary outcomes of complete spontaneous bowel movement (CSBM) and PAC‐SYM mean score improvement (decrease in score of >1 from the baseline).
Results
A total of 4323 women underwent screening, of which 780 fulfilled the Rome IV criterion, and 360 consented to participate (180 randomized to PEG and lactulose, respectively). Data from 247 women who completed the study were analyzed. CSBM was achieved in 107/124 (86.3%) versus 102/123 (82.9%) (RR 1.04, 95% CI: 0.93–1.16, P = 0.464) for PEG and lactulose trial arms, respectively. PAC‐SYM mean score improvement was 62/118 (52.5%) in the PEG arm versus 44/118 (37.3%) in the lactulose arm (RR 1.40, 95% CI: 1.05–1.88). Of secondary outcomes, a significant difference was found in favor of PEG, with respect to PAC‐SYM abdominal symptoms subscale, normal stool versus loose stool consistency and side effects of vomiting and diarrhea. After controlling for parity, baseline PAC‐SYM, PAC‐QoL scores, characteristics different at baseline, only diarrhea and loose stools remained significant.
Conclusion
Both PEG 4000 and lactulose are effective laxatives in pregnancy with similar performance after adjusted analysis. Diarrhea and loose stools are less frequently reported with PEG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Faculty of Medicine, University Malaya, Jalan Profesor Diraja Ungku Aziz, Kuala Lumpur, Malaysia.
ORCID-Profile: Peng Chiong Tan
Zitieren
APA
Raj, V. I., Hassan, A., Hanafiah, N., Azhary, J. M. K., Lim, B. K., Saaid, R., Gan, F., & Tan, P. C. (2024). Polyethylene glycol compared to lactulose for constipation in pregnancy: A randomized controlled trial. International Journal of Gynecology & Obstetrics, 166(2), 828-836. https://doi.org/10.1002/ijgo.15431
Vancouver
Raj VI, Hassan A, Hanafiah N, Azhary JMK, Lim BK, Saaid R, et al. Polyethylene glycol compared to lactulose for constipation in pregnancy: A randomized controlled trial. International Journal of Gynecology & Obstetrics. 2024;166(2):828-836. doi:10.1002/ijgo.15431
BibTeX
@article{Raj2024,
author = {Raj, Victoria Ivy and Hassan, Azyyati and Hanafiah, Nurulashikin and Azhary, Jerilee Mariam Khong and Lim, Boon Kiong and Saaid, Rahmah and Gan, Farah and Tan, Peng Chiong},
title = {Polyethylene glycol compared to lactulose for constipation in pregnancy: A randomized controlled trial},
journal = {International Journal of Gynecology & Obstetrics},
year = {2024},
volume = {166},
number = {2},
pages = {828--836},
doi = {10.1002/ijgo.15431}
}
EUVIMED